Depots for cancer |
(VPGVG)120
|
Tyrosine residue for conjugation of 125I or 131I radionuclides |
[97] |
(VPGVG)60, 120, or 240
|
1, 4, or 7 tyrosine residues for conjugation of 125I or 131I radionuclides |
[98] |
(VPGXG)160 or 168 X=A14V1C1 or VaCb where a:b=15:1, 9:1, or 5:1 |
Cysteine residues for disulfide cross-linking and tyrosine residues for conjugation of 125I radionuclide |
[99] |
Depots for joint degeneration |
(VPGVG)47 kDa
|
14C labeling for visualization of prolonged residence in rat knee joint |
[100] |
(VPGXG)90 X=V5G3A2 and (VPGVG)30
|
IL-1Ra for anti-inflammatory treatment of osteoarthritis |
[101] |
[(VPGKG)-(VPGVG)16]6
|
Lysine residues for THPP cross-linking and physical encapsulation of vancomycin and cefazolin antibiotics |
[102] |
Depots for neuroinflammation |
(VPGVG)120
|
Tritium radiolabeling for visualization of prolonged residence in perineural space |
[103] |
(VPGVG)60
|
sTNFRII for anti-inflammatory treatment of dorsal root ganglion |
[104, 105] |
(VPGXG)60, 80, or 160 X=V1I3E1
|
Glutamate residues for conjugation of curcumin with degradable carbamate linker |
[106] |
Depots for diabetes |
(VPGVG)120
|
GLP-1 fusion for release of macromolecular peptide drug carrier |
[107] |
(VPGVG)240
|
(GLP-1)6 fusion via protease cleavable arginine linkers for release of free peptide drug |
[108] |